Compare
Atea Pharmaceuticals, Inc. vs Omeros Corp vs Keros Therapeutics, Inc. vs Zentalis Pharmaceuticals, Inc.
| Latest fiscal year | Atea Pharmaceuticals, Inc. AVIR | Omeros Corp OMER | Keros Therapeutics, Inc. KROS | Zentalis Pharmaceuticals, Inc. ZNTL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $244.06M | $0 |
| Revenue growth (YoY) | n/a | n/a | n/m | -100.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | 27.7% | n/a |
| Net margin | n/a | n/a | 35.7% | n/a |
| Net income | -$158.35M | -$3.35M | $87.01M | -$137.06M |
| EPS (Diluted) | -$1.94 | -$0.05 | $2.30 | -$1.91 |
| Operating cash flow | -$132.03M | -$116.09M | $107.50M | -$125.25M |
| Free cash flow | n/a | -$116.16M | $105.95M | -$125.25M |
| Cash & equivalents | $95.71M | $9.66M | $287.42M | $35.99M |
| Total assets | $315.22M | $325.63M | $338.02M | $288.97M |
| Total liabilities | $39.78M | n/a | $34.89M | $72.76M |
| Shareholders' equity | $275.43M | -$121.23M | $303.13M | $216.20M |
| Return on year-end equity | -57.5% | n/a | 28.7% | -63.4% |
| Shares outstanding | 78.13M | 71.67M | 19.54M | 69.09M |
Revenue, most recent five fiscal years
| Fiscal year | Atea Pharmaceuticals, Inc. | Omeros Corp | Keros Therapeutics, Inc. | Zentalis Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $351.37M Ended 2021-12-31 | $73.81M Ended 2020-12-31 | $244.06M Ended 2025-12-31 | $0 Ended 2025-12-31 |
| 1 year earlier | $48.63M Ended 2020-12-31 | $111.81M Ended 2019-12-31 | $3.55M Ended 2024-12-31 | $67.42M Ended 2024-12-31 |
| 2 years earlier | n/a | $29.87M Ended 2018-12-31 | $151.0K Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $64.83M Ended 2017-12-31 | $0 Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | $41.62M Ended 2016-12-31 | $20.10M Ended 2021-12-31 | n/a |